(Q34129208)

31 July 2017

1 reference

title

Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence (English)

1 reference

31 July 2017

Suboptimal outcomes in patients with PKU treated early with diet alone: Revisiting the evidence (English)

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

15 June 2024

0 references

G. M. Enns

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678948

15 June 2024

R. Koch

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678948

15 June 2024

V. Brumm

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678948

15 June 2024

E. Blakely

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678948

15 June 2024

R. Suter

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678948

15 June 2024

E. Jurecki

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20678948

15 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20678948

15 June 2024

publication date

22 June 2010

1 reference

full work available at URL

31 July 2017

https://api.elsevier.com/content/article/PII:S1096719210002222?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

https://api.elsevier.com/content/article/PII:S1096719210002222?httpAccept=text/plain

15 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

Molecular Genetics and Metabolism

15 June 2024

published in

1 reference

31 July 2017

volume

101

1 reference

31 July 2017

issue

2-3

1 reference

31 July 2017

page(s)

99-109

1 reference

National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Stability of blood phenylalanine levels and IQ in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Response monitoring in children with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Autism and phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Interhemispheric interaction during childhood: II. Children with early-treated phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Patterns of academic achievement among patients treated early with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Executive functioning, memory, and learning in phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Executive functioning and speed of processing in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Effects of dietary management of phenylketonuria on long-term cognitive outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Inhibitory control in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison with diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Frontal lobe-dependent functions in treated phenylketonuria: blood phenylalanine concentrations and long-term deficits in adolescents and young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

School performance in early and continuously treated phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Wechsler subscale IQ and subtest profile in early treated phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Short-term dietary interventions in children and adolescents with treated phenylketonuria: effects on neuropsychological outcome of a well-controlled population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Motor function under lower and higher controlled processing demands in early and continuously treated phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Phenylketonuria in adulthood: a collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Does dietary DHA improve neural function in children? Observations in phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Omega-3 LC-PUFA supply and neurological outcomes in children with phenylketonuria (PKU).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Derangement of the dopaminergic system in phenylketonuria: study of the event-related potential (P300)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Executive function impairment in early-treated PKU subjects with normal mental development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

A preliminary report on dopamine system reactivity in PKU: acute effects of haloperidol on neuropsychological, physiological, and neuroendocrine functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Executive functions in children with phenylketonuria: variations as a function of phenilalanine plasm level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

A neuropsychological profile of off-diet adults with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Behaviour in early treated phenylketonuria: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Behaviour and school achievement in patients with early and continuously treated phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Executive functioning in children and adolescents with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

State regulation and response inhibition in children with ADHD and children with early- and continuously treated phenylketonuria: an event-related potential comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Emotional outcome of adolescents and young adults with early and continuously treated phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Remarkable differences: the course of life of young adults with galactosaemia and PKU

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

MRI abnormalities in normal-appearing brain tissue of treated adult PKU patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Detecting 3D Corpus Callosum abnormalities in phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Blood-brain phenylalanine relationships in persons with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Reduced cerebral fluoro-L-dopamine uptake in adult patients suffering from phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Brain phenylalanine concentration in the management of adults with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Global and regional volume changes in the brains of patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Cerebral energy metabolism in phenylketonuria: findings by quantitative In vivo 31P MR spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Normal-appearing white matter in patients with phenylketonuria: water content, myelin water fraction, and metabolite concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Characterization of white matter alterations in phenylketonuria by magnetic resonance relaxometry and diffusion tensor imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Cerebral glucose metabolism in adults with early treated classic phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Serum levels of neural protein S-100B in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Iron status of children with phenylketonuria undergoing nutrition therapy assessed by transferrin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

A randomized trial of long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Iron and protein sufficiency and red cell indices in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Protein insufficiency and linear growth restriction in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Fish oil supplementation improves visual evoked potentials in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Randomised controlled trial of essential fatty acid supplementation in phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Lipophilic antioxidants in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Cognitive functions and the antioxidant system in phenylketonuric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Total homocysteine, B-vitamins and genetic polymorphisms in patients with classical phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Dietary long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The impact of phenylketonuria on folate metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Lipid status and long-chain polyunsaturated fatty acid concentrations in adults and adolescents with phenylketonuria on phenylalanine-restricted diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Platelet serotonin concentrations in PKU patients under dietary control and tetrahydrobiopterin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Fat intakes of children with PKU on low phenylalanine diets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Low total antioxidant status is implicated with high 8-hydroxy-2-deoxyguanosine serum concentrations in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Increased plasma adiponectin concentrations in poorly controlled patients with phenylketonuria normalize with a strict diet: evidence for catecholamine-mediated adiponectin regulation and a complex effect of phenylketonuria diet on atherogenesis ris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Oxidative stress in patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The essential fatty acid status in phenylketonuria patients under treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Carnitine status in early-treated children, adolescents and young adults with phenylketonuria on low phenylalanine diets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Intake and blood levels of fatty acids in treated patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Plasma thiols and their determinants in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

NORMAL FATTY ACID CONCENTRATIONS IN YOUNG CHILDREN WITH PHENYLKETONURIA (PKU).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Protein metabolism in adult patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Peak bone mass in patients with phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Phalangeal quantitative ultrasound in children with phenylketonuria: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Intake of major nutrients by women in the Maternal Phenylketonuria (MPKU) Study and effects on plasma phenylalanine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Barriers to successful dietary control among pregnant women with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Maternal phenylketonuria: the French survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Maternal Phenylketonuria Collaborative Study (MPKUCS)--the 'outliers'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Maternal phenylketonuria: report from the United Kingdom Registry 1978-97

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Follow up of fetal outcome in cases of maternal phenylketonuria in Northern Ireland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Nutrient intake and congenital heart defects in maternal phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Maternal phenylketonuria in Western Australia: pregnancy outcomes and developmental outcomes in offspring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The Resource Mothers Study of Maternal Phenylketonuria: preliminary findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Management of phenylketonuria in Europe: survey results from 19 countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Dietary management practices in phenylketonuria across European centres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

PKU-what is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

When should clinical guidelines be updated?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

How practical are recommendations for dietary control in phenylketonuria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The truth of treating patients with phenylketonuria after childhood: the need for a new guideline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Living with phenylketonuria: perspectives of patients and their families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Blood phenylalanine estimation for the patient with phenylketonuria using a portable device

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Future treatment strategies in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

First drug approved for treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.017

inferred from DOI database lookup

7 January 2021

based on heuristic

Cognitive functions in patients with phenylketonuria in long-term treatment with tetrahydrobiopterin

24

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

Psychological adjustment of children with phenylketonuria

15 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

Quality of life in noncompliant adults with phenylketonuria after resumption of the diet

15 June 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

MR imaging-based volumetry in patients with early-treated phenylketonuria

15 June 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

Brain white matter lesions of children with phenylketonuria before and after treatment

15 June 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

15 June 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

Investigation of a phenylalanine-biosensor system for phenylketonuria detection

15 June 2024

163

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

NIH Consensus Statement on Management of Hepatitis C: 2002

15 June 2024

180

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

NIH consensus development conference targets prevention and management of hepatitis C

15 June 2024

181

1 reference

https://api.crossref.org/works/10.1016/J.YMGME.2010.05.017

15 June 2024

Identifiers

1 reference

31 July 2017

1 reference